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Background: Studies have reported conflicting results regarding the potential benefit 
of prolonged release (PR) fampridine in other domains besides walking. Moreover, 
only a small number of studies have explored long- term effects of PR fampridine. The 
aim of this study was to assess cognitive function, quality of life, mood and fatigue in 
MS patients treated with fampridine after 6 and 12 months of treatment. 
Methods: IGNITE was an observational, open label study. Subjects were examined 
with the timed 25-foot walk (T25FW) and the BICAMS battery and were asked to 
complete the Multiple Sclerosis Impact Scale (MSIS-29), Modified Fatigue Impact Scale 
(MFIS), Beck Depression Inventory-II (BDI-II) and MS International Quality-of-Life 
questionnaire (MUSIQOL) at baseline and at weeks 24 and 48. Patients were sub-
grouped into responders (n:40) and non-responders (n:20) according to T25FW 
performance after 2 weeks on treatment. 
Results: After 6 months, statistically significant improvement was observed on T25FW 
(p<0.001), SDMT (p<0.001) and MSIS29 (p<0.001), for responders. After 1 year on 
treatment, statistically significant improvement was observed in T25FW (p <0.001), 
MSIS29 (p=0.004), SDMT (p<0.001) and MUSIQOL (p=0.03) for responders. There were 
no statistically significant improvements for the non-responders. 
Conclusions: PR Fampridine may have a beneficial effect on information processing 
speed though not on memory. Study data provide some evidence that fampridine 
treatment may reduce the impact of MS on daily activities and improve quality of life 
but has no effect on subjective fatigue and mood.  
 
















Multiple sclerosis (MS) is  one of the most common disabling diseases of the Central 
Nervous System (CNS) especially during early adult life [1].Walking difficulties  occur 
often  during the course  of the disease and interfere with daily activities of people 
with MS (PwMS).[2,3]Walking impairment is considered one of the most disabling 
symptoms of the disease, according to PwMS ,[4] while there is increasing evidence 
that deterioration of gait in the absence of active inflammatory processes might be 
one of the symptoms signaling the transition from relapsing-remitting to secondary 
progressive MS[5]. Cognitive impairment occurs in about half of PwMS, [6] fatigue is 
the most commonly reported symptom [7] and mood disturbances are frequently 
observed [8]. These all have a negative impact on patients’ everyday functioning, 
ability to work and quality of life. [9] 
Fampridine is a potassium channel blocker that improves the impaired axonal 
conduction associated with CNS demyelination [10] and has been approved as a 
symptomatic treatment, for the improvement of walking in adult PwMS with walking 
disability (EDSS 4-7). According to phase III studies, [11,12]   38% of patients presented 
an average 25% improvement in the ttimed 25 Foot Walk (T25FW), while post 
marketing studies have suggested that the percentage of responders may be higher. 
[13-15]. The long-term impact of prolonged release (PR) fampridine in walking has also 
been studied and findings suggest a sustained beneficial effect in walking ability 
[16,17] In addition, several studies explored the potential benefits of PR fampridine in 
cognition, fatigue and quality of life of PwMS with conflicting results [18-22].  
The aim of this investigator initiated, observational study (an Investigator Initiated 
Observational Study to Evaluate the Long-Term Effects of Prolonged-release 
Fampridine on Cognitive Performance, Fatigue, Depression and Quality of Life in MS 
Patients. ‘IGNITE’) was to assess cognitive function, quality of life, depression and 
fatigue in adult PwMS, after 6 months and 1 year on treatment with PR fampridine.  
Together with the identified need for real life data regarding the use of PR fampridine 
in the everyday clinical setting, the results from this study may provide additional 
information regarding the selection of appropriate candidates for PR fampridine 
treatment. 
 
2.Materials and methods 
 
2.1 Study population  
Sixty adult MS patients (31 females; age 51 ± 9.4) fulfilling the Greek prescription 
guidelines for PR fampridine were recruited to this investigator initiated, open label, 
prospective study. Testing was conducted in the Multiple Sclerosis Center of AHEPA 
University Hospital, was approved by the ethical committee of Aristotle University of 
Thessaloniki and was performed in accordance with the ethical standards of the 
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Helsinki Declaration. Patients included in the study had to be free of relapses or 
disease progression for at least 3 months and not been exposed to fampridine in the 
past. Since concomitant symptomatic treatment for fatigue and mood could interact 
with study results, we recruited patients not willing to receive antidepressants, 
stimulants, anxiolytics or a psychotherapeutic intervention of any kind.  All patients 
provided written informed consent prior to participation in the study.  
 
2.2 Study Design 
Patients were evaluated regarding their disability status and walking speed by an 
experienced neurologist. Cognitive assessment was performed by a trained 
neuropsychologist in a quiet room with no distractions. In addition, all patients   were 
asked to complete self-administered questionnaires about quality of life (QoL), impact 
of MS in daily activities, fatigue and mood. Visits were performed at baseline and after 
6 and 12 months. After 2 weeks on treatment with PR fampridine, patients were re-
evaluated regarding walking ability and sub grouped into responders and non-
responders depending on their walking performance as measured by T25FW. An 
improvement of at least 20% in T25FW performance was used to designate 
responders in most of the patients; for those with a baseline performance less or equal 
to 8 seconds, an improvement of at least 15% was considered indicative of a 
responder [21]. Non-responders discontinued PR fampridine but were assessed in the 
same follow ups as responders. Detailed records of any adverse events were kept and 
adherence to treatment was also taken into account.  The study flow chart is 
presented in figure 1. 





2.3 Assessment tools 
Patients’ disability was assessed on the Expanded Disability Status Scale (EDSS) and 
walking ability was evaluated using the T25FW. Patients’ cognitive function was 
assessed using the Greek validated version of the BICAMS battery. [23,24] This 
comprised the Symbol Digit Modality Test (SDMT, information processing speed) [25], 
Greek Verbal Learning Test (GVLT, verbal memory) [26] and Brief Visuospatial Memory 
Test Revised (BVMT-R, visual memory) [27]. The total number of words and items 
across learning trials was used for scoring the GVLT and BVMT-R tests.  Alternate forms 
were used for each visit in order to avoid practice effects. Patients were also asked to 
complete the Modified Fatigue Impact Scale (MFIS) [28],  
the Beck Depression Inventory -II (BDI-II) [29], the Multiple Sclerosis Impact Scale [30] 
(MSIS-29) and the MS International Quality-of-Life questionnaire (MusiQoL) [31]. 
 
2.4 Statistical analysis 
To conduct the statistical analysis, IBM SPSS Statistics Version 23 was used. First, 
descriptive statistics were calculated and data were tested for their normality with 
Shapiro-Wilk Test. Paired Samples t-test and non-parametric Wilcoxon Signed Rank 
test were implemented for normal and not normal distributed data respectively, to 
evaluate the impact of the drug administration on patient’s scores on the tests that 





Overall, 33 (82.5%) responders and 19 (95%) non-responders completed all visits. 
Patients’ demographics and disease characteristics are presented in table 1. Subgroup 
demographics were comparable in some extent, regarding age p:0.19 and disease 
duration p:0.87. Among the responders, the percentages of patients according to the 
type of their disease were: Relapsing Remitting MS (RRMS) 27,5%, Primary Progressive 
(PPMS) 35% and Secondary Progressive (SPMS) 37,5%. Alternatively, 61% of RRMS, 
82,3% of PPMS and 60% of SPMS responded to treatment. Moreover, baseline 
assessments were similar between responders and non-responders, besides lower 
baseline MSIS-29 and T25FW performance in the responders’ group. Detailed data 








Table 1. patients’ demographics and disease characteristics at baseline, after 2, 24 and 48 
weeks. (R: responders, NR: non-responders, RR: relapsing-remitting, PP: primary progressive, 





Table 2: Performance of both groups in baseline, week 24 and week 48. All p values 
correspond to group comparisons regarding baseline performance. Statistically significant 
probability values are presented in italics. Total number of items recalled across the learning 
trials was used for scoring   GVLT and BVMT-R. Results are presented as mean (SD). R: 
responders, NR: non-responders. 
 
EDSS: Expanded Disability Status Scale, T25FW: Timed 25 Foot Walk, BICAMS: Brief International Cognitive 
Assessment in MS, SDMT: Symbol Digit Modalities Test, GVLT: Greek Verbal Learning Test, BVMT-R: Brief 
Visuospatial Memory Test Revised, MFIS: Modified Fatigue Impact Scale, BDI-II: Beck Depression Inventory-II, MSIS-
29: Multiple Sclerosis Impact Scale, MusiQoL: MS International Quality-of-Life questionnaire. 
Timepoint baseline  Week 2 Week 24  Week 48 
 All patients R NR R NR R NR 
 Number of patients (n) 60 40 20 35 19 33 19 
 Females (%) 31 (51,6%) 19(47.5%) 12(60%) 17(48.5%) 11(57.8%) 15(45.4%) 11(57.8%) 
 Mean (median ) age 51 (51) 52.5 (51.5) 48 (50) 52.4(52) 48(51) 52.5(53) 48(51) 
 Mean (median) years from diagnosis  13.7(13) 14(14) 12.9 (10) 14.4(14) 13.2(12) 14.1(14) 13.2(12) 
Mean (median) EDSS score  5.5 (6.0) 5.3(5.5) 5.4 (5.5) 5.3(5.5) 5.9(6.0) 5.3(5.5) 5.9(6.0) 
Type of MS (RR-PP-SP) 18-17-25 11-14-15 7-3-10 11-11-13 7-2-10 9-11-13 7-2-10 
Measures   Baseline Week 24 Week 48 
 R NR R p value NR p value R p value NR p value 
Number (n) 35 19 35  19  33  19  
EDSS  5.4(0.8) 5.8 (0.7) 5.3(0.9) 0.22 5.9(0.7) 0.74 5.3(0.9) 0.73 6.0 (0.6) 0.37 
T25FW 15.6(9.5) 21.7(15.9) 12.3(7.9) <0.001 25.3(19.9) 0.54 12.8 (8.2) <0.001 25.6(18.6) 0.49 
BICAMS           
       SDMT 32.0(13.6) 33.7(14.6) 35.6(14.6) <0.001 33.6(14.7) 0.98 34.7(14.3) <0.001 34.8(14.2) 0.82 
       GVLT  49.6(13.5) 50(6.9) 51.0(11.8) 0.09 50(6.5) 1.00 50(11.5) 0.8 51.4(6.5) 0.52 
       BVMT-R 14.1(6.2) 13 (6.2) 14.3(6.1) 0.66 13.6(5.9) 0.75 14.8 (6.6) 0.28 13.1(6.6) 0.9 
MFIS  total 43.9(14.4) 43.3(13.8) 42.7(13.7) 0.33 43.6(13) 0.82 41.2(13.2) 0.08 41.2(14.6) 0.09 
           Cognitive  14.8 (8.8) 13.1(7.2) 14.2(7.9) 0.55 13.1(5.8) 1.00 12.9(7.2) 0.15 11.2(7) 0.15 
           Physical 24.2 (6.1) 24.3 (7) 24.5 (6.3) 0.68 25.7 (6.6) 0.33 23.8 (6.4) 0.71 24.8(7.6) 0.70 
           Psychosocial 4.6(1.6) 5.3 (1.8) 4.8(1.9) 0.48 4.8 (1.4) 0.15 4.6(1.6) 0.92 5.1(1.5) 0.63 
BDI-II 12.1(6.4) 14.1(6.8) 12.4(7.1) 0.66 12.5(4.4) 0.40 11.5(4.9) 0.67 12.2(5.1) 0.35 
MSIS-29 71.6 (14.4) 76.5(17.4) 65.2(13.4) <0.001 74.5(13.3) 0.33 64.8(13.9) 0.04 75.6(13.1) 0.66 




3.1 Disability status and walking ability  
Regarding disability status as measured by EDSS, no statistically significant change was 
observed by weeks 24 or 48 in both groups (responders p=0.22, p=0.73 respectively, 
non-responders p=0.74, p=0.37 respectively). However, there was some individual 
variation. Six responders demonstrated a 0.5-1-point improvement in EDSS score after 
fampridine treatment due to change in their ambulation score. Four responders and 
seven non-responders had a higher EDSS compared to baseline by the end of the 
study. Walking ability, as expected, improved with statistical significance for the 
responders group at both week 24 and 48, but not in the non-responders group, when 
compared to baseline. (responders week 24 p<0.001; week 48 p<0.001). 
 
3.2 Cognitive function 
Both groups were assessed with the BICAMS battery at baseline, 6 and 12 months, 
using alternate forms at each visit. Regarding cognitive processing speed, statistically 
significant improvement in SDMT performance was observed in the responders group 
at both week 24 (p<0.001) and 48 (p<0.001), but not in the non-responders group (p 
=0.98, p=0.82 respectively). At week 24, responders demonstrated a mean change of 
3.63 ± 3.18 points in SDMT performance, compared to -0.11 ± 1.97 for non-responders 
(p=0.0001). By week 48, responders presented a mean change of 3.12 ± 2.89, 
compared to 1.05 ± 2.07 for non-responders (p=0.0008) (figure 2). 
 




n                   35                                                           33  









 To investigate the clinical significance of the SDMT results, the criterion of 4-points 
change was applied [32,33]. In the responders group, in week 24, 18/35 (51,4%) 
demonstrated a 4-point improvement, while the rest presented changes less or equal 
to ±3 points and thus were classified as stable. In week 48, 17/33 (51.5%) of 
responders presented at least a 4-point improvement in SDMT performance and the 
rest remained stable. No patient in the responder group presented a decline in the 
performance by more than 4 points.  In the non-responders group, in week 24, a 4-
point improvement was observed in 1/19 (5.2%), while in week 48 2/19 (10.5%) 
patients demonstrated a 4 -point improvement and 1/19 (5.5%) patient presented a 
4-point decline on SDMT performance (figure 3). There were no significant changes in 
verbal or visual memory function, for either group, at either time point (table 2). 
 
Figure 3. Percentage of patients with clinically meaningful change in Symbol Digit Modalities 







3.3 Fatigue, Mood and Quality of Life 
There were also no significant changes in fatigue or mood for either group, at either 
time point (table 2). However, there was a significant improvement in MSIS-29 for the 
responders at both time points, compared to baseline (week 24, p<0.001; week 48, 
p=0.04). There was no improvement in MS impact for the non-responders at either 
time point (figure 4). Responders also reported improvement in quality of life by the 
end of the study (week 24 p=0.1; week 48 p=0.03). Once again, there was no 
improvement in quality of life for the non-responders at either time point (figure 5). 
 
 
Figure 4: Subjects’ score in MSIS-29 questionnaire. * p=0.05, ** p<0.001. 
 
 








 Overall, adverse events possibly related to treatment were mild and the majority of 
them occurred during the first two weeks. Gastrointestinal disturbances and dizziness 
were the two most frequently reported events. Both were mild and self -limited. One 
patient reported a urinary tract infection which resolved with antibiotics. All other 
adverse events resolved without the need for any action. All adverse events possibly 
related to treatment are presented in table 3. Regarding adverse events non-related 
to treatment, a patient experienced a severe relapse and therefore left the study. Also, 
one patient presented Grade II lymphopenia due to concomitant disease modifying 
treatment (DMT).  
 
 










The potential benefits of PR fampridine on other functions besides walking ability have 
been studied before, however few studies have investigated the effect of fampridine 
Adverse event Number of events %  of patients 
Gastrointenstinal disturbances 2 3.3 
Diziness 2 3.3 
Back pain 1 1.6 
Headache 1 1.6 
Itching 1 1.6 




treatment in the longer term. Improvements in walking ability over a year or more 
have frequently been reported in responders [17,18,34]. The effect we reported of 
improved walking reducing EDSS scores for responders on fampridine has been 
previously noted [34]. Our study has reported significant improvements for 
responders at 6 and 12 months on information processing speed, measured by the 
SDMT, but not on verbal or visual memory. About 50% of MS patients treated with 
fampridine presented a clinically meaningful improvement in SDMT scores after both 
6 and 12 months. 
These findings are in accordance with previous studies that used SDMT as an outcome 
measure. In particular, Jensen et al. reported improvement in SDMT scores after 1 
month of fampridine treatment [19]. In a small study with 10 PPMS patients, 
improvement in SDMT scores was observed after 6 months on treatment. [35] More 
recently, in a study with 134 patients and 77 healthy controls, improvement in 
information processing speed was demonstrated after 6 months on fampridine 
treatment. [36]  
A previous fampridine study showed significant improvement for information 
processing speed, as measured by the PASAT, after 9-12 months of treatment [18]. 
Another study with four weeks’ fampridine treatment in a crossover design reported 
no treatment effect for information processing speed, again measured on the PASAT 
[37]. An even shorter study with 14 days’ Dalfampridine treatment failed to show a 
treatment effect on the PASAT [34].   
Impaired information processing speed in MS has been attributed to a ‘disconnection 
syndrome’ [38]; transmission of high speed signals may be weakened in   
demyelinated axons. Fampridine penetrates the blood-brain barrier [39] and improves 
impaired axonal conduction by selectively blocking potassium channels [40], therefore 
an improvement of conduction in cognitive circuits could explain our study results. 
However, this potential mechanism should further be explored with experimental 
research. Interestingly, although preclinical studies have suggested a role for specific 
potassium channels in learning and memory [41], in this study no beneficial effects of 
PR fampridine were observed regarding memory. Impairment in memory is often 
observed in MS and is attributed to delayed retrieval due to the mechanisms described 
above but may also require the integrity of specific areas involved in memory storage. 
[42,43]. 
Patient reported outcomes regarding the impact of MS in everyday functioning and 
quality of life may provide important additional information to clinicians regarding 
response to treatment [44,45]. In this study, a sustained improvement regarding the 
impact of MS in daily instrumental activities, as measured by MSIS-29, was observed. 
An overall improvement of quality of life was also reported after one year on 
fampridine treatment and these findings might reflect the improvement in walking 
ability and cognitive processing speed also observed in the responders group. Our 
results are consistent with previous findings. An improvement in MSIS-29 scores was 
observed after 6 months treatment with fampridine in a previous double-blind study. 
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[46] The large, open label ENABLE study’s participants demonstrated significant 
improvement in health-related quality of life, measured by the SF-36. [13] and 
patients treated with fampridine have also reported improvement in working ability 
and social life [47].                         
In this study there was a trend towards improvement in fatigue among responders, 
but this did not reach statistical significance. A recent double-blind, placebo-
controlled study with 32 MS patients reported improvement in physical fatigue after 
2-years of fampridine treatment. [20] A treatment effect on fatigue after only 14 days’ 
Dalfampridine treatment has been reported [34]. The four-week treatment crossover 
trial of fampridine reported a significant treatment effect on cognitive fatigue, 
determined by comparing performance on early and late PASAT items [37]. We found 
no significant change in mood.   
Interestingly enough, the vast majority of the PPMS patients were responders, despite 
the general though not evidence – based impression for the contrary. However, in the 
long-term efficacy studies of fampridine in MS [16,17] no valid correlation was 
detected between patient’s responsiveness to fampridine and the specific type of MS, 
whereas PPMS patients exhibited significant positive effects. 
 This open label observational study provided data to support the potential benefits 
of fampridine treatment in various domains besides walking ability. However, there 
are several limitations of this study, such as the small sample size. The impact of DMTs 
and physiotherapy were not taken into consideration as possible confounding factors. 
However, none of the patients switched DMT 6 months prior to the study and during 
the study duration. In addition, subjects with the progressive forms of the disease 
were over represented in this study. We also selected patients who were not taking 
symptomatic medications. Since this was a non-interventional study, the non-
responder group did not continue on the medication. However, these patients might 
have responded in certain cognitive aspects apart from their response to walking.  
Large scale, double blind studies could further explore the long-term impact of PR 
fampridine in various domains and provide more robust findings.  
 
5. Conclusions 
The IGNITE study demonstrated a significant improvement in cognitive processing 
speed and impact of MS in daily activities after fampridine treatment. Study data have 
provided some evidence that fampridine treatment may have a longer term beneficial 
effect on quality of life, but not on mood and fatigue. The mechanism that explains 
why some patients respond to treatment whilst others do not, remains to be explored 
in future studies. Further investigation regarding brain and cognitive reserve may 
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